NeuroEM Therapeutics is a Phoenix-based medical device company committed to developing, clinically testing, and marketing Transcranial Electromagnetic Treatment (TEMT) as an effective prevention and treatment for Alzheimer’s Disease & other neurodegenerative diseases.

NeuroEM Therapeutics is clinically testing and plans to market a self-contained head device that, if clinically successful, will provide “in home” electromagnetic treatment to the brains of Alzheimer’s patients. While providing treatment for 1-2 hours per day, the head device will not hinder daily activities. We believe the device will directly attack the Alzheimer’s Disease process. It would be available through neurologists and other health professions who diagnosis memory disorders.

Management / Advisors


Founder and CEO

Dr. Arendash was a Full Professor and Research Professor at the University of South Florida for 30 years. During the last 6 years there, he directed the Florida Alzheimer’s Disease Research Center’s Animal Core. Dr. Arendash’s research expertise involves development of therapeutics against Alzheimer’s Disease. He has published over 100 peer-reviewed articles in first tier journals, including Science, Nature and the Journal of Alzheimer’s Disease – the last of which he has held the position of Senior Editor. During his academic career at USF, Dr. Arendash was awarded $5 million in research support from extramural granting agencies, including the National Institutes of Health (NIH), the Alzheimer’s Disease and Related Disease Association (ADRDA), and the United Parkinson’s Association. Dr. Arendash was among the very first to provide evidence that Alzheimer’s Disease starts in the brain decades before it is diagnosed. As well, he and his colleagues published initial evidence that immunotherapy was a viable approach to AD. Publication of Dr. Arendash’s landmark study in 2010 providing the first evidence that electromagnetic treatment provides cognitive benefit to Alzheimer’s mice resulted in worldwide interest from the news media. At NeuroEM Therapeutics, Dr. Arendash has integrated his management of the company with his involvement in both its clinical and basic science program. He received his Ph.D in Neuroscience/Physiology at the University of California, San Francisco (UCSF). Dr. Arendash then did his post-doctoral research at UCLA’s Brain Research Institute prior to joining the faculty at the University of South Florida.


Advisor for Product Development

Robert Baranowski is Founder and President of Left Coast Engineering (Escondido, CA). He leads most of the design projects for the company. With more than 25 years of electrical design experience for both military and commercial projects, Rob also has extensive hardware design experience in wireless, power, audio, controllers, location-aware and sensors. His software design and development experience involves user interfaces, drivers and applications. Rob and Left Coast Engineering have designed, tested, and produced the MemorEM 1000 head devices utilized by NeuroEM Therapeutics in the company’s Phase I clinical trial. He is an inventor on 20 issued patents, as well as on several CIP and PCT applications submitted by NeuroEM Therapeutics. Previously, Rob was with Sony and Motorola in their cellular design and special projects groups. He holds a Masters of Electrical Engineering from Villanova University. Active in the community, Rob has founded a non-profit instructional baseball program and coaches high school baseball.


Advisor for Strategic Planning and Technology

Eric is a business pioneer, futurist, serial inventor, serial entrepreneur, and angel investor. He is the President of Remarkable Technologies, Inc., a company he founded in 1994. In the 1980s, Eric created what many now recognize as one of the world’s first global “e-commerce” systems. In 1996, he created one of the world’s first online travel agencies. Eric has commercialized many product and service innovations across a wide variety of industries. Particularly pertinent, Eric has multiple patents in RF technologies, including those for breakthroughs in dimensional reductions of antenna systems. In 2016, Eric’s company granted an exclusive license to NeuroEM for its patented (U.S. 9,238,149) technology for a parallel application of electromagnetic energy via a head device. On the marketing side of his career, for 13 years Eric held multiple senior roles at Connecticut’s largest advertising agency. He then helped bring to life a Web-development company that grew to over 250 employees, spanning 18 offices in 13 countries. Eric is an active angel investor and member of the Connecticut-based Angel Investor Forum “AIF”. He helps fund new independent ventures across many business sectors, and is instrumental in bringing to life innovations arising through his own company.


Advisor for Strategic Planning and Financing

Patty is a passionate supporter of entrepreneurs. In 2009 she was noted in Quora as “one of the great women to know in the NYC venture space”. She had just completed what would become a multi $100MM exit, her final deal at Dakota Ventures. In 2010 she decided to immerse herself in the building of Connecticut’s Innovation Ecosystem (CTnext). She founded one of Connecticut’s first Innovation Centers/ Shared Workspaces, which launched in early 2012, and was honored with a CT Woman of Innovation nomination. Patty continues to advise/coach high growth IT, BioTech & ‘Green’ Tech startups. Her focus is on helping entrepreneurs raise angel and venture capital, and In the past five years her portfolio companies have raised ~$100M. Patty’s career includes 20+ years in Venture Capital, Investment Banking, and Technology, as an Investor, Advisor, & Business Development Professional. She holds a Master’s Degree from Wharton and did her undergraduate work at Colorado College and CU-Boulder…a city that has now emerged as a Mecca for entrepreneurs.

Board of Directors

Gary W. Arendash, Ph.D.

As the Founder and CEO of NeuroEM Therapeutics, Dr. Arendash is also serving as Chairman of its Board of Directors.

Edward Goodwin, Ph.D.

Dr. Goodwin’s scientific career spans 36 years in bioinformatics, cell, and molecular biology. His patented work from graduate school is still used in the high-level production of many important therapeutics including Rituxan, the number one selling anti-cancer drug. As a fellow and later a faculty member in the Yale Department of Genetics, he used a cervical cancer model system to discover that the genes involved in the very early stages of cancer sensitize tumor cells to treatments that downregulate those genes, a process later popularized as “oncogene addiction”. He also discovered pathways leading tumor cells to spontaneously “age” in a process called induced senescence whereby rapidly growing cells cease proliferation within one day of treatment and adopt the characteristics of normal cells grown to exhaustion over many months of cell culture. His Yale career culminated in the discovery of genes essential for infection by DNA tumor viruses and architecture of the nuclear envelope. As an avid Angel Investor and entrepreneur for the past 10 years, Dr. Goodwin has personally investing in 34 early stage companies and is a past president and current board member of the Angel Investor Forum, Connecticut’s largest Angel Investor group. He continues to advise many companies on topics ranging from fundraising to hard science and business strategy and has twice served as the Chief Technical Officer for Connecticut bioscience companies. He is an active panelist, speaker and judge in the startup community and is often solicited for opinions regarding bioscience investment.


Mr. St. Lawrence is the Chief Trustee of The Glass Charitable Foundation. The Foundation provided all funds necessary to perform and complete NeuroEM’s Phase I clinical trial in Alzheimer’s subjects. As such, the Foundation is a major holder of stock in NeuroEM. Mr. St. Lawrence was Director of Business Development at Rogers Corporation prior to his current position as Principle Director at Argyle Enterprises, which implements investments in early stage biotechnology companies.

Collaborators / Partners

Medical Device Development

  • Left Coast Engineering

    Rob Baranowski,
    Senior Engineering Project Lead

  • RF Exposure Lab

    Jay Moulton, Vice-President

  • Ocotillo Electromagnetics:

    David Wittwer, Ph.D.
    Richard Ziolkowski, Ph.D.

  • Remarkable Technologies

    Eric Knight, President

  • Zurich Med Tech

    Niels Kuster, Ph.D.

Clinical Trials

  • USF Health/Byrd Alzheimer’s Institute

    Amanda Smith MD
    Haitham Abulaban, MBBS, CCRC

  • University Diagnostic Institute

    John Arrington, M.D.

  • Invicro/Konica Minolta

    Gary Wisniewski, Ph.D.
    Lino Becerra, M.D.

Basic Science/SBIR Research

  • University of South Florida

    Dr. Chuanhai Cao, Ph.D.
    Ziaopeng Li, Ph.D.
    Jing Wang, Ph.D.

Scientific Advisory Board

Huntington Potter, Ph.D.

Dr. Huntington Potter is Professor of Neurology, member of the Linda Crnic Center for Down Syndrome, and Director of the Rocky Mountain Alzheimer’s Disease Center at the University of Colorado Anschutz Medical Campus. He is devoted to studying the mechanistic relationship between Alzheimer’s Disease and Downs syndrome, recognizing that these disorders are two sides of the same coin.  Prior to joining UC Denver, Dr. Potter studied, researched and taught for 30 years at Harvard University. He received his AB Cum Laude in Physics and Chemistry and his MA and PhD in Biochemistry and Molecular Biology before spending 13 years on the faculty of the Neurobiology Department. In 1998, Dr. Potter joined the Faculty at the University of South Florida as the Eric Pfeiffer Chair for Research on Alzheimer’s Disease. He designed and directed the NIA-designated Florida Alzheimer’s Disease Research Center at USF and from 2004-2008 he was CEO of the Johnnie B. Byrd Sr. Alzheimer’s Center & Research Institute  during this time, the Institute built the largest free-standing Alzheimer’s disease research institute in the world.  Dr. Potter discovered that Alzheimer’s disease and Down syndrome, which invariably leads to Alzheimer’s by age 30-40, are mechanistically related to each other through the development of cells with abnormal numbers of chromosomes; this is the focus of his current research at UC Denver. He is author of over 100 scientific articles/books and is the holder of 15 U.S. and foreign patents.  In 2010, Dr. Potter was elected a Fellow of the American Association for the Advancement of Science and was selected one of Colorado’s Top Thinkers of 2013 by the Denver Post.  His electron micrographs of DNA are on permanent exhibit in the National American History Museum of the Smithsonian Institute in Washington D.C.

Richard Caselli, M.D.

Dr. Caselli is Associate Director and Clinical Core Director of the Alzheimer’s Disease Center at Mayo Clinic in Arizona, which focuses on symptomatic patients with mild cognitive impairment and dementia.  He is also a Professor of Neurology at Mayo Clinic’s College of Medicine.  Dr. Caselli has served at Mayo’s Scottsdale campus since 1990 and is also recent Past Chairman of Mayo’s Department of Neurology.  He holds an adjunct clinical faculty appointment at the Biodesign Institute at Arizona State University, serves as an Adjunct Professor at ASU’s Department of Biomedical Informatics, and currently is a Member of the Advisory Board of the Center for Services Leadership of the W.P. Carey School of Business at ASU.  Dr. Caselli also serves on the board of directors of the Arizona Alzheimer’s Consortium.  He is certified by the American Board of Electrodiagnostic Medicine, American Board of Neurology and Psychiatry, and National Board of Medical Examiners. Dr. Caselli received both his M.D. and bachelor’s degrees from Columbia University in New York.  He served an internship and residency at Mayo Graduate School of Medicine and a fellowship in behavioral neurology and cognitive neuroscience at the University of Iowa College of Medicine.  The research program of Dr. Caselli focuses on cognitive aging and the changes that can be detected before the symptomatic onset of memory loss and related symptoms of Alzheimer’s disease.  His personal focus is on the neuropsychological and related behavioral changes in AD that can be detected.  Through a close series of collaborations, he is also involved in brain imaging (FDG-PET, PIB-PET and MRI), neuropathology, genomics, and epigenetic factors that influence Alzheimer’s disease risk and age of onset.

Ranjan Duara, M.D.

Dr. Duara is the Medical Director of the Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center. He is also Associate Director of the University of Florida/Mt. Sinai Alzheimer’s Disease Research Center, and director of its clinical core based at Mount Sinai.  Through his work as co-director and clinical core leader of the Florida Alzheimer’s Disease Research Center and principal investigator of the Alzheimer’s Disease Initiative’s Florida Brain Bank, Dr. Duara has helped to enhance what is known about the biology of the disease. In May 2005, Dr Duara and his team, in collaboration with the Johnnie Byrd Alzheimer’s Institute at the University of South Florida in Tampa, received a prestigious grant from the National Institutes of Health (NIH) to become one of 31 Alzheimer’s Disease Research Centers (ADRC) in the U.S to conduct cutting-edge research on Alzheimer’s. Dr. Duara is an Associate Professor of Medicine, Neurology and Psychiatry at the University of Miami School of Medicine.  He completed neurology residencies in the United Kingdom and at Thomas Jefferson University Hospital in Philadelphia, and did a fellowship in neuroscience and neuroimaging at the National Institutes of Health. His research has focused primarily on early diagnosis of Alzheimer’s disease and other dementias, neuroimaging, genetic epidemiology, and the methodology for staging the transition from normal cognitive aging to dementia. He has contributed to more than 150 articles in peer-review scientific journals and has been an investigator in numerous clinical trials of novel agents for the treatment of Alzheimer’s Disease. Dr. Duara is also the chair and organizer of the Mild Cognitive Impairment Symposium, which is held annually in Miami Beach.